SCHEMBL30925474

SCHEMBL30925474

CCn1ccnc1S(=O)(=O)Nc1ccc(C)c2cccnc12

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 11/20 0.60
▸ TDP1 Q9NUW8 3/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ CKS1B P61024 4/20 0.46
▸ SKP2 Q13309 4/20 0.46
▸ PKM P14618 1/20 0.46
▸ HTT P42858 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ GFER P55789 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ SLC6A2 P23975 1/20 0.41
▸ GLO1 Q04760 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30925426 0.91 SLC40A1 (0.48) SLC40A1TDP1MEN1KMT2ACKS1B
SCHEMBL27214301 0.88 SLC40A1 (0.59) SLC40A1TDP1MEN1KMT2ACKS1B
SCHEMBL30925523 0.88 SLC40A1 (0.59) SLC40A1TDP1MEN1KMT2ACKS1B
SCHEMBL26964545 0.88 SLC40A1 (0.59) SLC40A1TDP1MEN1KMT2ACKS1B
SCHEMBL27214296 0.88 SLC40A1 (0.59) SLC40A1TDP1MEN1KMT2ACKS1B
SCHEMBL26964251 0.87 MEN1 (0.45) SLC40A1TDP1MEN1KMT2ACKS1B
SCHEMBL29800832 0.87 MEN1 (0.45) SLC40A1TDP1MEN1KMT2ACKS1B
SCHEMBL30553417 0.86 MEN1 (0.56) SLC40A1TDP1MEN1KMT2ACKS1B
SCHEMBL26964389 0.86 MEN1 (0.56) SLC40A1TDP1MEN1KMT2ACKS1B
SCHEMBL27214162 0.85 SLC40A1 (0.43) SLC40A1TDP1MEN1KMT2ACKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885TDP1 4247/4885MEN1 2604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback